{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:06:07Z","timestamp":1758402367473,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002769","name":"Bushehr University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s43440-020-00172-5","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T07:02:47Z","timestamp":1603350167000},"page":"1676-1684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Low-dose angiotensin AT1 receptor \u03b2-arrestin-biased ligand, TRV027, protects against cisplatin-induced nephrotoxicity"],"prefix":"10.1007","volume":"72","author":[{"given":"Abdolhamid","family":"Esmaeeli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaveh","family":"Tanha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Assadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-8270","authenticated-orcid":false,"given":"Mohammad","family":"Seyedabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"issue":"8","key":"172_CR1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00204-012-0821-7","volume":"86","author":"NA dos Santos","year":"2012","unstructured":"dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol [Internet]. 2012;86(8):1233\u201350.","journal-title":"Arch Toxicol [Internet]"},{"issue":"9","key":"172_CR2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/CAD.0000000000000537","volume":"28","author":"D Yuwen","year":"2017","unstructured":"Yuwen D, Mi S, Ma Y, Guo W, Xu Q, Shen Y, Shu Y. Andrographolide enhances cisplatin-mediated anticancer effects in lung cancer cells through blockade of autophagy. Anticancer Drugs [Internet]. 2017;28(9):967\u201376.","journal-title":"Anticancer Drugs [Internet]"},{"issue":"9","key":"172_CR3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int [Internet]. 2008;73(9):994\u20131007.","journal-title":"Kidney Int [Internet]"},{"issue":"2","key":"172_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115\u201324.","journal-title":"Am J Med Sci"},{"key":"172_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2016.12.031","volume":"797","author":"A Wzgarda","year":"2017","unstructured":"Wzgarda A, Kleszcz R, Prokop M, Regulska K, Regulski M, Paluszczak J, et al. Unknown face of known drugs - what else can we expect from angiotensin converting enzyme inhibitors? Eur J Pharmacol [Internet]. 2017;797:9\u201319.","journal-title":"Eur J Pharmacol [Internet]"},{"issue":"10","key":"172_CR6","doi-asserted-by":"crossref","first-page":"F807","DOI":"10.1152\/ajprenal.00266.2015","volume":"309","author":"SA Johnson","year":"2015","unstructured":"Johnson SA, Spurney RF. Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy. Am J Physiol Ren Physiol [Internet]. 2015;309(10):F807\u201320.","journal-title":"Am J Physiol Ren Physiol [Internet]"},{"issue":"5","key":"172_CR7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/phrs.2002.0959","volume":"45","author":"SSV Padi","year":"2002","unstructured":"Padi SSV, Chopra K. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res [Internet]. 2002;45(5):413\u201320.","journal-title":"Pharmacol Res [Internet]"},{"issue":"5","key":"172_CR8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s004670050173","volume":"10","author":"A Anarat","year":"1996","unstructured":"Anarat A, Noyan A, Gonlusen G, Duman N, Tuncer D. Influence of enalapril on experimental cyclosporin A nephrotoxicity. Pediatr Nephrol [Internet]. 1996;10(5):616\u201320.","journal-title":"Pediatr Nephrol [Internet]"},{"issue":"3","key":"172_CR9","first-page":"255","volume":"21","author":"SM el El-Sayed","year":"2008","unstructured":"el El-Sayed SM, Abd-Ellah MF, Attia SM. Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. Pak J Pharm Sci. 2008;21(3):255\u201361.","journal-title":"Pak J Pharm Sci"},{"issue":"6","key":"172_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000262453","volume":"55","author":"S Saleh","year":"2009","unstructured":"Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy [Internet]. 2009;55(6):399\u2013406.","journal-title":"Chemotherapy [Internet]"},{"issue":"8","key":"172_CR11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3109\/0886022X.2012.700886","volume":"34","author":"M Haghighi","year":"2012","unstructured":"Haghighi M, Nematbakhsh M, Talebi A, Nasri H, Ashrafi F, Roshanaei K, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences. Ren Fail [Internet]. 2012;34(8):1046\u201351.","journal-title":"Ren Fail [Internet]"},{"key":"172_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/2277-9175.175253","volume":"5","author":"Z Zamani","year":"2016","unstructured":"Zamani Z, Nematbakhsh M, Eshraghi-Jazi F, Talebi A, Jilanchi S, Navidi M, et al. Effect of enalapril in cisplatin-induced nephrotoxicity in rats; gender-related difference. Adv Biomed Res [Internet]. 2016;5:14.","journal-title":"Adv Biomed Res [Internet]"},{"issue":"1","key":"172_CR13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.kint.2016.03.031","volume":"90","author":"SL Goldstein","year":"2016","unstructured":"Goldstein SL, Mottes T, Simpson K, Barclay C, Muething S, Haslam DB, et al. A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. Kidney Int [Internet]. 2016;90(1):212\u201321.","journal-title":"Kidney Int [Internet]"},{"issue":"3","key":"172_CR14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CAD.0000000000000191","volume":"26","author":"MT Spiotto","year":"2015","unstructured":"Spiotto MT, Cao H, Mell L, Toback FG. Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer. Anticancer Drugs [Internet]. 2015;26(3):343\u20139.","journal-title":"Anticancer Drugs [Internet]"},{"issue":"2","key":"172_CR15","first-page":"99","volume":"70","author":"K Almanric","year":"2017","unstructured":"Almanric K, Marceau N, Cantin A, Bertin \u00c9. Risk factors for nephrotoxicity associated with cisplatin. Can J Hosp Pharm [Internet]. 2017;70(2):99\u2013106.","journal-title":"Can J Hosp Pharm [Internet]"},{"key":"172_CR16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2019.05.006","volume":"200","author":"M Seyedabadi","year":"2019","unstructured":"Seyedabadi M, Ghahremani MH, Albert PR. Biased signaling of G protein coupled receptors (GPCRs): molecular determinants of GPCR\/transducer selectivity and therapeutic potential. Pharmacol Ther [Internet]. 2019;200:148\u201378.","journal-title":"Pharmacol Ther [Internet]"},{"issue":"4","key":"172_CR17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1742-4658.2011.08459.x","volume":"279","author":"M Seyedabadi","year":"2012","unstructured":"Seyedabadi M, Ostad SN, Albert PR, Dehpour AR, Rahimian R, Ghazi-Khansari M, et al. Ser\/ Thr residues at \u03b13\/\u03b25 loop of G\u03b1s are important in morphine-induced adenylyl cyclase sensitization but not mitogen-activated protein kinase phosphorylation. FEBS J [Internet]. 2012;279(4):650\u201360.","journal-title":"FEBS J [Internet]"},{"issue":"7201","key":"172_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature07063","volume":"454","author":"JH Park","year":"2008","unstructured":"Park JH, Scheerer P, Hofmann KP, Choe H-W, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature [Internet]. 2008;454(7201):183\u20137.","journal-title":"Nature [Internet]"},{"issue":"3","key":"172_CR19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4330\/wjc.v9.i3.200","volume":"9","author":"A Lymperopoulos","year":"2017","unstructured":"Lymperopoulos A, Aukszi B. Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: implications for heart failure therapy. World J Cardiol [Internet]. 2017;9(3):200.","journal-title":"World J Cardiol [Internet]"},{"key":"172_CR20","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1038\/srep08116","volume":"5","author":"S Dabul","year":"2015","unstructured":"Dabul S, Bathgate-Siryk A, Valero TR, Jafferjee M, Sturchler E, McDonald P, et al. Suppression of adrenal \u03b2arrestin1-dependent aldosterone production by ARBs: head-to-head comparison. Sci Rep [Internet]. 2015;5:8116.","journal-title":"Sci Rep [Internet]"},{"issue":"3","key":"172_CR21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/jpet.110.173005","volume":"335","author":"JD Violin","year":"2010","unstructured":"Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al. Selectively engaging \u03b2-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther [Internet]. 2010;335(3):572\u20139.","journal-title":"J Pharmacol Exp Ther [Internet]"},{"issue":"1\u20132","key":"172_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11010-017-3046-5","volume":"434","author":"H Fatemikia","year":"2017","unstructured":"Fatemikia H, Seyedabadi M, Karimi Z, Tanha K, Assadi M, Tanha K. Comparison of 99mTc-DMSA renal scintigraphy with biochemical and histopathological findings in animal models of acute kidney injury. Mol Cell Biochem [Internet]. 2017;434(1\u20132):163\u20139.","journal-title":"Mol Cell Biochem [Internet]"},{"issue":"2","key":"172_CR23","first-page":"110","volume":"25","author":"K Tanha","year":"2017","unstructured":"Tanha K, Fatemikia H, Assadi M, Seyedabadi M. Assessment of the maximum uptake time of 99mTc-DMSA in renal scintigraphy in rat. Iran J Nucl Med [Internet]. 2017;25(2):110\u20134.","journal-title":"Iran J Nucl Med [Internet]"},{"issue":"4","key":"172_CR24","first-page":"481","volume":"52","author":"D Wellington","year":"2013","unstructured":"Wellington D, Mikaelian I, Singer L. Comparison of ketamine-xylazine and ketamine-dexmedetomidine anesthesia and intraperitoneal tolerance in rats. J Am Assoc Lab Anim Sci. 2013;52(4):481\u20137.","journal-title":"J Am Assoc Lab Anim Sci"},{"issue":"22","key":"172_CR25","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","volume":"99","author":"S Ishida","year":"2002","unstructured":"Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA. 2002;99(22):14298\u2013302.","journal-title":"Proc Natl Acad Sci USA"},{"key":"172_CR26","first-page":"47","volume":"1","author":"MH Hanigan","year":"2003","unstructured":"Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther [Internet]. 2003;1:47\u201361.","journal-title":"Cancer Ther [Internet]"},{"issue":"3\u20134","key":"172_CR27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.etp.2007.05.005","volume":"59","author":"MA Hye Khan","year":"2007","unstructured":"Hye Khan MA, Abdul Sattar M, Abdullah NA, Johns EJ. Cisplatin-induced nephrotoxicity causes altered renal hemodynamics in Wistar Kyoto and spontaneously hypertensive rats: role of augmented renal alpha-adrenergic responsiveness. Exp Toxicol Pathol. 2007;59(3\u20134):253\u201360.","journal-title":"Exp Toxicol Pathol"},{"issue":"1","key":"172_CR28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12885-017-3135-6","volume":"17","author":"K Komaki","year":"2017","unstructured":"Komaki K, Kusaba T, Tanaka M, Kado H, Shiotsu Y, Matsui M, et al. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study. BMC Cancer. 2017;17(1):144.","journal-title":"BMC Cancer"},{"issue":"6","key":"172_CR29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000446371","volume":"90","author":"T Mizuno","year":"2016","unstructured":"Mizuno T, Hayashi T, Shimabukuro Y, Murase M, Hayashi H, Ishikawa K, et al. Lower blood pressure-induced renal hypoperfusion promotes cisplatin-induced nephrotoxicity. Oncology. 2016;90(6):313\u201320.","journal-title":"Oncology"},{"issue":"11","key":"172_CR30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00286776","volume":"14","author":"AM Peters","year":"1988","unstructured":"Peters AM, Jones DH, Evans K, Gordon I. Two routes for 99mTc-DMSA uptake into the renal cortical tubular cell. Eur J Nucl Med. 1988;14(11):555\u201361.","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"172_CR31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1476-5381.1993.tb13877.x","volume":"110","author":"L Criscione","year":"1993","unstructured":"Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 1993;110(2):761\u201371.","journal-title":"Br J Pharmacol"},{"key":"172_CR32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjp.0707323","volume":"151","author":"MT Le","year":"2007","unstructured":"Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT(1) receptor. Br J Pharmacol. 2007;151:952\u201362.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"172_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","volume":"12","author":"S Miura","year":"2011","unstructured":"Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst [Internet]. 2011;12(1):1\u20137.","journal-title":"J Renin Angiotensin Aldosterone Syst [Internet]"},{"issue":"4","key":"172_CR34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0976-500X.171880","volume":"6","author":"S Das","year":"2015","unstructured":"Das S, Bandyopadhyay S, Ramasamy A, Prabhu VV, Pachiappan S. A case of losartan-induced severe hyponatremia. J Pharmacol Pharmacother [Internet]. 2015;6(4):219\u201321.","journal-title":"J Pharmacol Pharmacother [Internet]"},{"issue":"1","key":"172_CR35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","volume":"54","author":"Y Miao","year":"2011","unstructured":"Miao Y, Dobre D, Heerspink HJL, Brenner BM, Cooper ME, Parving H-H, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia. 2011;54(1):44\u201350.","journal-title":"Diabetologia"},{"issue":"5","key":"172_CR36","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.HYP.21.5.704","volume":"21","author":"MR Goldberg","year":"1993","unstructured":"Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertens (Dallas, Tex 1979). 1993;21(5):704\u201313.","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"172_CR37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5049\/EBP.2013.11.2.56","volume":"11","author":"D-R Kim","year":"2013","unstructured":"Kim D-R, Cho J-H, Jang W-S, Kim J-S, Jeong K-H, Lee T-W, et al. Severe hyponatremia associated with the use of angiotensin II receptor blocker\/thiazide combinations. Electrolyte Blood Press E BP. 2013;11:56\u20139.","journal-title":"Electrolyte Blood Press E BP"},{"issue":"6823","key":"172_CR38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","volume":"304","author":"S Bjorck","year":"1992","unstructured":"Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M, Bj\u00f6rck S, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ [Internet]. 1992;304(6823):339\u201343.","journal-title":"BMJ [Internet]"},{"issue":"3","key":"172_CR39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-11-0122","volume":"210","author":"VP Bilan","year":"2011","unstructured":"Bilan VP, Salah EM, Bastacky S, Jones HB, Mayers RM, Zinker B, et al. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol. 2011;210(3):293\u2013308.","journal-title":"J Endocrinol"},{"issue":"4","key":"172_CR40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ki.1996.161","volume":"49","author":"S Ishidoya","year":"1996","unstructured":"Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int. 1996;49(4):1110\u20139.","journal-title":"Kidney Int"},{"issue":"3","key":"172_CR41","doi-asserted-by":"crossref","first-page":"F854","DOI":"10.1152\/ajprenal.00059.2007","volume":"293","author":"I Zafar","year":"2007","unstructured":"Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007;293(3):F854\u20139.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"172_CR42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/1440-1681.12511","volume":"43","author":"C Kocak","year":"2016","unstructured":"Kocak C, Kocak FE, Akcilar R, Bayat Z, Aras B, Metineren MH, et al. Effects of captopril, telmisartan and bardoxolone methyl (CDDO-Me) in ischemia-reperfusion-induced acute kidney injury in rats: an experimental comparative study. Clin Exp Pharmacol Physiol. 2016;43(2):230\u201341.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"172_CR43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/phrs.1998.0432","volume":"39","author":"MA Mansour","year":"1999","unstructured":"Mansour MA, El-Kashef HA, Al-Shabanah OA. Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats. Pharmacol Res. 1999;39(3):233\u20137.","journal-title":"Pharmacol Res"},{"issue":"1\u20133","key":"172_CR44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejphar.2012.04.027","volume":"685","author":"S Okui","year":"2012","unstructured":"Okui S, Yamamoto H, Li W, Gamachi N, Fujita Y, Kashiwamura S-I, et al. Cisplatin-induced acute renal failure in mice is mediated by chymase-activated angiotensin-aldosterone system and interleukin-18. Eur J Pharmacol [Internet]. 2012;685(1\u20133):149\u201355.","journal-title":"Eur J Pharmacol [Internet]"},{"issue":"2","key":"172_CR45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00392-017-1168-0","volume":"107","author":"G Cotter","year":"2018","unstructured":"Cotter G, Davison BA, Butler J, Collins SP, Ezekowitz JA, Felker GM, et al. Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. Clin Res Cardiol. 2018;107(2):170\u201381.","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"172_CR46","doi-asserted-by":"crossref","first-page":"H1001","DOI":"10.1152\/ajpheart.00475.2012","volume":"303","author":"K-S Kim","year":"2012","unstructured":"Kim K-S, Abraham D, Williams B, Violin JD, Mao L, Rockman HA. beta-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol. 2012;303(8):H1001\u201310.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"172_CR47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/bph.13338","volume":"173","author":"P Mukhopadhyay","year":"2016","unstructured":"Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, et al. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016;173(3):446\u201358.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"172_CR48","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00588.2016","volume":"313","author":"Y Wang","year":"2017","unstructured":"Wang Y, Huang J, Liu X, Niu Y, Zhao L, Yu Y, et al. beta-Arrestin-biased AT1R stimulation promotes extracellular matrix synthesis in renal fibrosis. Am J Physiol Renal Physiol. 2017;313(1):F1-8.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"172_CR49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000474960","volume":"137","author":"E \u00d3 hAinmhire","year":"2017","unstructured":"\u00d3 hAinmhire E, Humphreys BD. Fibrotic changes mediating acute kidney injury to chronic kidney disease transition. Nephron [Internet]. 2017;137(4):264\u20137.","journal-title":"Nephron [Internet]"},{"issue":"3","key":"172_CR50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1152\/physiolgenomics.00037.2017","volume":"50","author":"M Hultstrom","year":"2018","unstructured":"Hultstrom M, Becirovic-Agic M, Jonsson S. Comparison of acute kidney injury of different etiology reveals in-common mechanisms of tissue damage. Physiol Genomics. 2018;50(3):127\u201341.","journal-title":"Physiol Genomics"},{"key":"172_CR51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-050214-013407","volume":"67","author":"A Zuk","year":"2016","unstructured":"Zuk A, Bonventre JV. Acute kidney injury. Ann Rev Med. 2016;67:293\u2013307.","journal-title":"Ann Rev Med"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00172-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T07:39:51Z","timestamp":1723793991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00172-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["172"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00172-5","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"29 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interests with respect to the publication of the manuscript in the current format.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}